Income Statement
QUOIN PHARMACEUTICALS, LTD.
QNRX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
- | - | - | - |
|
Operating Expenses
|
16.29 | 9.53 | 9.38 | 9.26 |
|
Research & Development
|
9.80 | 3.60 | 3.31 | 2.67 |
|
Selling, General & Administrative
|
6.49 | 5.93 | 6.07 | 6.58 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-16.29 | -9.53 | -9.38 | -9.26 |
|
Non-Operating Income
|
0.49 | 0.57 | 0.69 | -0.12 |
|
Interest Income
|
0.48 | - | - | 0.10 |
|
Interest Expense
|
- | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - |
|
Income Before Tax
|
-15.80 | - | - | - |
|
Income Tax Expense
|
- | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-15.80 | -8.96 | -8.69 | -9.38 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-16.29 | -9.53 | -9.38 | -9.26 |
|
Earnings Per Share (Basic)
|
-14.80 | -1.91 | -9.64 | -3.90 |
|
Diluted EPS
|
-14.80 | -1.91 | -9.64 | -3.90 |
|
Weighted Average Shares
|
1.07 | 4.69 | 0.90 | 2.42 |
|
Diluted Weighted Avg Shares
|
1.07 | 4.69 | 0.90 | 2.42 |
|
Comprehensive Income
|
-15.81 | - | - | - |